Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
71,6 CHF | -0,69% | +0,28% | +40,67% |
Vakgebied
Aantal werknemers: 319
Verkoop per activiteit
CHF in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Own Products
52,0
%
| 43 | 60,6 % | 53 | 52,0 % | +25,05% |
Licence Fees, Up-front Fees and Milestones
23,8
%
| 6 | 8,5 % | 24 | 23,8 % | +310,51% |
Generic Products, Specialty Drugs and Related Services
12,9
%
| 14 | 19,4 % | 13 | 12,9 % | -3,41% |
Royalties
9,7
%
| 6 | 8,6 % | 10 | 9,7 % | +63,17% |
Other
1,6
%
| 2 | 2,9 % | 2 | 1,6 % | -17,40% |
Verkoop per regio
CHF in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Italy
100,0
%
| 70 | 100,0 % | 102 | 100,0 % | +45,72% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 61 | 01-01-06 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01-06-16 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Luigi Longo
CTO | Chief Tech/Sci/R&D Officer | 45 | 01-06-05 |
Davide Malavasi
CTO | Chief Tech/Sci/R&D Officer | 51 | 01-09-11 |
Marco Lecchi
COO | Chief Operating Officer | 60 | 01-01-01 |
Hazel Winchester
IRC | Investor Relations Contact | 53 | 10-01-22 |
Nhan Ngo Dinh
PRN | Corporate Officer/Principal | 45 | - |
Biagio Viganò
HRO | Human Resources Officer | 50 | - |
Diana Harbort
PRN | Corporate Officer/Principal | 57 | 01-01-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 28-05-21 |
Founder | 69 | 01-01-97 | |
Director/Board Member | 64 | 01-01-06 | |
Director/Board Member | 69 | 01-04-12 | |
Director/Board Member | 65 | 01-03-16 | |
Chief Executive Officer | 61 | 01-01-06 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 17 543 522 | 7 805 026 ( 44,49 %) | 1 490 681 ( 8,497 %) | 44,49 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
1 283 390 | 7.32% | 101 593 999 $ |
Bedrijfsgegevens
Cosmo Pharmaceuticals NV
Riverside II Sir John Rogerson's Quay
2, Dublin
+353 1 817 0370
http://www.cosmopharma.comBedrijven van de groep
Naam | Categorie en sector |
---|---|
Pharmaceuticals: Major
| |
Cosmo Technologies Ltd.
Cosmo Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Dublin, Ireland. Cosmo Technologies was acquired by Salix Pharmaceuticals Ltd. from Cosmo Pharmaceuticals SA. |
Pharmaceuticals: Major
|
Granell Strategic Investment Fund Ltd.
|
Investment Managers
|
Sector
Verkoop per activiteit
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,67% | 1,26 mld. | |
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |
- Beurs
- Aandelen
- Koers COPN
- Onderneming Cosmo Pharmaceuticals N.V.